#Switzerland #Geneva #Neurotherapeutics #MindMaze #AnnualGeneralMeeting

MindMaze Therapeutics to Hold Annual General Meeting in 2026

MindMaze Therapeutics Holding SA, listed on SIX as MMTX, is a pioneer in scalable neurotherapeutics that has recently released details regarding its 2026 Annual General Meeting (AGM). Scheduled for June 25, 2026, at 11:00 a.m. CEST, the event will take place in Geneva, Switzerland. This meeting is a significant occasion for shareholders as it will include key developments regarding the company's governance and financial performance.

At the upcoming AGM, the Board of Directors is set to propose the re-election of its current members. Additionally, there will be a proposal to elect two new board members: Brad Hollinger, who is the Founder, Chairman, and CEO of Vibra Healthcare, and Zach Henderson, who is the current CEO of MindMaze Therapeutics. Their addition to the board signals an effort to strengthen the company’s leadership as it continues to pave the way in the field of neurotherapeutics.

The AGM agenda will cover several important items, including:

• - Approval of the 2025 Annual Report and financial statements
• - Elections for the Nomination and Compensation Committee members
• - Selection of the Independent Proxy and statutory auditors
• - Discussions regarding compensation for the Board of Directors and Executive Committee
• - A shareholder vote on increasing the Company's conditional share capital.

For shareholders, the outcomes of these votes are critical as they may directly influence the company's strategic direction and compensation structures. MindMaze encourages all shareholders to participate actively in these decisions.

MindMaze Therapeutics aims to redefine recovery pathways for patients globally. By leveraging advanced software, proprietary sensors, and AI-driven analytics, the company creates a continuum of care that spans from acute hospital settings to outpatient therapies and even home-based care. Their innovative approach addresses the increasing shortage of specialized clinicians in the neurology field and aims to provide scalable, reimbursable solutions for conditions such as stroke and Parkinson’s disease.

The products developed by MindMaze are not only FDA-cleared but also carry CE marks, ensuring that they meet high safety and efficacy standards. With a robust research and development pipeline and a commitment to rigorous clinical validation, MindMaze stands at the forefront of neurorestorative medicine.

Further information regarding the specific proposals and AGM details can be found on MindMaze's official website. As the date approaches, stakeholders are urged to stay informed and prepared for an engaging meeting.

MindMaze’s vision is clear: through innovation and commitment to patient care, it seeks to enhance quality of life and expedite recovery for those suffering from neurological disorders.

Through this AGM, MindMaze Therapeutics not only aims to address current performance but also to set the stage for future growth and development in the dynamic field of neurotherapeutics.

For more updates on this event and other company developments, shareholders and interested parties should visit MindMaze's website.